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Abstract
Introduction Lymphocyte infiltration (LI) is often seen in breast
cancer but its importance remains controversial. A positive
correlation of human epidermal growth factor receptor 2 (HER2)
amplification and LI has been described, which was associated
with a more favorable outcome. However, specific lymphocytes
might also promote tumor progression by shifting the cytokine
milieu in the tumor.
Methods Affymetrix HG-U133A microarray data of 1,781
primary breast cancer samples from 12 datasets were included.
The correlation of immune system-related metagenes with
different immune cells, clinical parameters, and survival was
analyzed.
Results A large cluster of nearly 600 genes with functions in
immune cells was consistently obtained in all datasets. Seven
robust metagenes from this cluster can act as surrogate markers
for the amount of different immune cell types in the breast
cancer sample. An IgG metagene as a marker for B cells had no
significant prognostic value. In contrast, a strong positive
prognostic value for the T-cell surrogate marker (lymphocyte-
specific kinase (LCK) metagene) was observed among all
estrogen receptor (ER)-negative tumors and those ER-positive
tumors with a HER2 overexpression. Moreover ER-negative
tumors with high expression of both IgG and LCK metagenes
seem to respond better to neoadjuvant chemotherapy.
Conclusions Precise definitions of the specific subtypes of
immune cells in the tumor can be accomplished from microarray
data. These surrogate markers define subgroups of tumors with
different prognosis. Importantly, all known prognostic gene
signatures uniformly assign poor prognosis to all ER-negative
tumors. In contrast, the LCK metagene actually separates the
ER-negative group into better or worse prognosis.
Introduction
There is growing evidence that interaction of stromal and
immune cells with normal or malignant epithelial cells is pivotal
for the development and progression of cancer. Several
reports indicate that tumor-infiltrating leucocytes may repre-
sent an essential pathophysiological factor in the development
and progression of breast cancer [1-3]. Their prognostic
impact, however, remains unclear. Lymphocyte infiltration (LI)
is often seen in breast cancer and has been suggested as a
marker of host antitumor immune response, but its importance
in terms of pathophysiology and prognosis or treatment pre-
diction remains controversial. The presence of B cells is
already seen with premalignant breast tumors [4], while T-cell
infiltration is associated only with high-grade ductal carcinoma
in situ and invasive carcinoma [5] and has been reported to
range from 1% to 45% of the total cellular mass [6].
ER: estrogen receptor; HER2: Human epidermal growth factor receptor 2; LCK: lymphocyte specific kinase; LI: lymphocyte infiltration; MHC: major 
histocompatibility complex; PBS: phosphate-buffered saline; SCL: stem-cell like; STAT1: signal transducer and activator of transcription 1.Breast Cancer Research    Vol 11 No 2    Rody et al.
Page 2 of 13
(page number not for citation purposes)
In rapidly proliferating tumors LI has been shown to be a good
prognostic indicator, correlating with lymph-node negativity,
smaller tumor size, and lower grade [7]. Similarly, Ménard and
colleagues have shown that lymphocyte infiltration of breast
cancer had a strong positive prognostic value in patients
younger than 40 years; no association was seen among
patients 40 years or older, however, suggesting a correlation
with estrogen receptor (ER) status or specific breast cancer
subtypes [8]. A positive correlation of human epidermal
growth factor receptor 2 (HER2) amplification/overexpres-
sion, LI and expression of lymphocyte-associated genes has
been described that was associated with a more favorable
outcome [9]. Only a small fraction of tumor-associated lym-
phocytes display activation markers, however, and there is no
definitive proof of cytotoxic activity of these cells against the
tumor in vivo [10]. In this context the expression of specific
oncoproteins such as HER2 or p53 is supposed to be immu-
nogenic [11].
The search for prognostic or predictive signatures using
microarray analysis in bulk breast cancer specimens reveals
several genes that are associated with immune cells; for exam-
ple, interferon-regulated genes [12,13], B-lymphocyte marker
[12], as well as T-lymphocyte-associated genes [13]. In this
context, whether these observations are due to an imbalance
of host-associated markers and tumor tissue or due to a real
biological phenomenon remains unclear. Data from gene
expression profiling of breast cancer cell lines showed that a
considerable number of immune-response-related genes
exhibit significant variable expression across the basal cell
subtype [14,15], suggesting that immune response genes
might play a crucial role even in the absence of host cells.
Most recently, Finak and colleagues identified a good-out-
come cluster from gene expression profiles of tumor stroma
that was isolated by laser-captured microdissection. This clus-
ter contained 22 different genes 'enriched for elements of the
T helper type 1 (TH1) immune response' of which the authors
verified selected markers by immunohistochemistry [16].
Overall, the impact of monocytes, B lymphocytes and T lym-
phocytes on prognosis is still a matter of debate. The purpose
of our study was therefore to accurately identify different clus-
ters of immune-cell-associated genes in bulk breast cancer
samples by a large-scale analysis of microarray datasets, and
to precisely analyze the correlation between the resulting
metagenes and specific breast cancer subtypes. Finally, we
evaluated the prognostic impact of these metagenes in
defined breast cancer subgroups.
Materials and methods
Microarray data
A database of 1,781 primary invasive breast cancers including
all samples from 12 Affymetrix HG-U133 microarray datasets
was established: Frankfurt [17,18] (Additional data file 1),
Uppsala [19], Oxford – Untreated [20], Stockholm [21], New
York [22], London [23], Rotterdam [24,25], Oxford –
Tamoxifen and Villejuif [26], Expression Project for Oncology
[27], Frankfurt-2 [28] (Additional data file 1), and MDA133
[29]. Characteristics of the individual datasets are presented
in Additional data file 1. Follow-up information was available for
1,263 patients. The median follow-up time was 79 months.
Seventy-two percent of all samples and 74% of those samples
with follow-up were ER-positive.
Only Affymetrix HG-U133A microarrays were included for full
comparability of all the probes on the arrays. Data were down-
loaded from the Gene Expression Omnibus website [30].
Affymetrix expression data for different immunological cell
types and tissues were obtained from Su and colleagues
[GEO:GSE1133] [31]. Affymetrix expression data were ana-
lyzed using the MAS5.0 algorithm [32] of the affy package
[33] from the Bioconductor software project [34]. Expression
data were log2-transformed and were normalized across each
individual array by a scaling factor S so that the magnitude
(sum of the squares of the values) equals one.
Metagenes for feature reduction
A high feature-to-sample ratio is one of the most important
problems in microarray research leading to an inflation of α val-
ues [35]. Unsupervised clustering was applied for feature
reduction based on the assumption that the expression of a
large number of genes is highly interdependent. This can be
attributed to the expression of sets of genes in different cell
types in the sample and to differentiation programs/pathways
associated with specific expression profiles. Genes that did
not show a correlation with other genes above a certain
threshold (0.7) were suspected to represent noise, and were
discarded from further analysis. To identify metagenes for the
principal vectors, we selected those clusters that contained at
least 10 elements and a minimal average correlation of 0.7 –
resulting in 199 total ProbeSets. Metagene expression values
were determined by calculating the mean of the normalized
expression values of all ProbeSets in the respective cluster.
Assessment of ER, HER2, proliferative status and tumors 
with stem-cell-like characteristics of the samples
To allow comparative analysis between different datasets and
since standard pathology for ER and HER2 was not available
for all samples, the receptor status was determined based on
Affymetrix expression data as previously described [36]. A
stem-cell-like (SCL) metagene was used as described previ-
ously [37,38]. This metagene was derived from 159 highly cor-
related Affymetrix ProbeSets and contains 35 out of 37 (95%)
previously reported markers of SCL breast cancers, undiffer-
entiated breast cancers and basal-like breast cancers [39-43].
Immunohistochemistry
To validate the presence of lymphocytes in those samples that
show a high expression of the respective metagenes, weAvailable online http://breast-cancer-research.com/content/11/2/R15
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performed immunohistochemistry using specific antibodies.
CD3 (clone F7.2.38; Dianova, Hamburg, Germany) and CD20
(clone B-Ly1; Dianova) were used as markers for T lymo-
phocytes and B lymphocytes, respectively.
Tissue samples of primary invasive breast cancer cases from
the University of Frankfurt were obtained with informed con-
sent and approval of the institutional review board of the Uni-
versity of Frankfurt. Briefly, paraffin sections (2 μm) were
mounted on Superfrost Plus slides, dewaxed in xylene and
rehydrated through graduated ethanol to water. Antigens were
retrieved by microwaving sections in 10 mM citrate buffer (pH
6.0) for 20 minutes at 800 W. Blocking was performed using
antibody dilution buffer (DCS Diagnostics, Hamburg, Ger-
many) at room temperature for 15 minutes. Antibodies were
subsequently diluted 1:100 individually in this buffer. Sections
were incubated with antibodies for 1 hour at room
temperature.
For negative controls, the primary antibodies were replaced
with PBS. For secondary antibody incubations and detection,
the Dako REAL Detection System Alkaline Phosphatase/RED
(Dako, Glostrup, Denmark) was used following the protocol of
the supplier and sections were counterstained with Mayer's
hematoxylin. Samples from the Frankfurt dataset were ranked
according to visual inspection of the amount of stained lym-
phocytes with the respective antibody in a blinded analysis.
The rank order was subsequently compared with that based
on the metagene expression using Spearman rank correlation.
Statistical analyses
All reported P values are two sided and P < 0.05 was consid-
ered to indicate a significant result. Subjects with missing val-
ues were excluded from the analyses. Fisher's exact test was
applied for associations between categorical parameters.
Spearman rank correlation was used to compare metagene
expression and results from immunohistochemistry. The
Kruskal–Wallis H test was used to analyze the relationship of
the expression of immune metagenes and pathological lym-
phocyte infiltration scores from the independent validation
dataset from London.
Survival intervals were measured from the time of surgery to
the time of death from disease or of the first clinical or radio-
graphic evidence of disease recurrence. Data for women in
whom the envisaged end point was not reached were cen-
sored as of the last follow-up date or at 120 months. We con-
structed Kaplan–Meier curves and used the log-rank test to
determine the univariate significance of the variables. Hazard
ratios were determined by Cox regression.
To examine simultaneously the effects of multiple standard
parameters and lymphocyte-specific kinase (LCK) metagene
expression on survival, a Cox proportional-hazards regression
model was applied among ER-negative samples. The effect of
each variable was assessed with the use of the Wald test and
described by the hazard ratio with a 95% confidence interval.
The model included binary variables for lymph node status
(lymph node-negative or N1), histological grading (G1 or G2
vs. G3), age (≤ 50 years vs. > 50 years), tumor size (≤ 2 cm
vs. > 2 cm), and HER2 status (by microarray [36]). All analyses
were performed using SPSS 15.0 (SPSS Inc., Chicago, IL,
USA) and R 2.6.2 software [44].
Results
Unsupervised hierarchical clustering of genes in individual
datasets as well as combined datasets revealed a large cluster
of genes with functions in immune cells. This cluster of approx-
imately 600 Affymetrix ProbeSets was consistently obtained in
all datasets with overall correlations of 0.2 to 0.3. We hypoth-
esized that the observed coordinated expression of subsets of
these genes might represent surrogate markers for the
amounts of different types of immune cells in the analyzed
samples. In addition, coordinated expression might result from
the induction of signaling pathways and specific differentiation
programs in the tumor cells themselves and/or accompanying
stromal tissue.
The expression of 569 Affymetrix ProbeSets from the immune-
related cluster was analyzed in a combined cohort of 1,230
samples to tease out relationships of these genes (see Addi-
tional data files 2, 3 and 4). To identify metagenes for the prin-
cipal expression vectors we selected those clusters that
contained at least 10 elements and a minimal average correla-
tion of 0.7, resulting in 199 total ProbeSets as shown in Figure
1a. Seven metagenes were derived as mean values of all
ProbeSets in the respective clusters (Figure 1b). The func-
tional annotation of the immune-system-related metagene
clusters is presented in Table 1 (a detailed list of all 199
ProbeSets is given in Additional data file 5).
Expression of the metagene clusters in different 
immunological cell types
To check the biological plausibility of the identified metagenes
as markers for cell types and/or an immunological state, we
analyzed their expression in different types of immune system
tissues and cell types (Figure 2). As expected, the IgG meta-
gene cluster seemed to be specific for B cells and those tis-
sues containing high amounts of these cells (tonsils, lymph
nodes, bone marrow). The hemopoietic cell kinase metagene
cluster displayed highest expression in peripheral blood CD14
monocytes and bone-marrow-derived CD33 myeloid cells, in
line with the well-known function of the hck gene in this line-
age. In contrast it is important to note that T cells of both the
CD4 and CD8 types are devoid of the expression of this meta-
gene (while some lower levels of expression are detected in
the B-cell lineage). Inversely to hemopoietic cell kinase, the
LCK metagene is expressed only in T cells but no expression
is observed in monocytes and the myeloid lineage. The MHC-
II metagene is only expressed by antigen-presenting cells butBreast Cancer Research    Vol 11 No 2    Rody et al.
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not in T cells, while high expression of the MHC-I metagene is
observed in all cell types as expected. The differences in the
interferon and signal transducer and activator of transcription
1 (STAT1) metagenes are smaller than those observed
Figure 1
Identification of immune-system-related metagenes Identification of immune-system-related metagenes. (a) To identify metagenes for the principal expression vectors we selected those gene clusters 
that encompassed at least 10 elements and displayed a minimal average correlation of 0.7 from the larger data matrix of 569 ProbeSets (see Addi-
tional data file 3). Expression of these selected 199 ProbeSets among the 1,230 breast cancer samples is shown. HCK, hemopoietic cell kinase; 
LCK, lymphocyte-specific kinase; MHC, major histocompatibility complex; STAT1, signal transducer and activator of transcription 1. (b) Seven meta-
genes were derived as mean values of all 199 ProbeSets from the seven clusters.Available online http://breast-cancer-research.com/content/11/2/R15
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between different tumor samples, which might suggest con-
siderable expression of those interferon-induced genes by the
carcinoma and/or stromal cells of the tumor.
Relationship of expression of immune-system-related 
metagenes with ER status, HER2 status and presence of 
stem-cell-like markers and lymphocyte infiltration
To analyze the relationship of the immune system metagenes
and standard parameters, unsupervised clustering analysis of
all 1,781 samples using the immune-related metagenes, ER,
HER2 as well as a metagene of SCL markers was performed
(Additional data file 6, Supplemental figure S2a). The results
suggested that considerable amounts of immune cells are
present among all different subtypes of tumors. Similar results
were obtained in the analysis of scatter plots comparing five
metagenes representing the major clusters (LCK, IgG, MHC-
II, interferon, STAT1) and ER and HER2 status (Additional
data file 6, Supplemental figure S2b). The scatter of LCK and
IgG (as well as MHC-II) metagenes showed a correlation (R2
= 0.52 and R2 = 0.62, respectively) that was not observed
between the interferon and IgG metagenes (R2 = 0.07). This
could suggest a parallel infiltration by both T cells and B cells
into those tumors that are characterized by high expression of
both metagenes. On the other hand, the interferon and STAT1
metagenes are also correlated (R2 = 0.52), which might repre-
sent an interferon response of tumor cells or other cell types in
the respective samples. In general, no clear relationship with
ER and HER2 status was seen in these scatter plots. ER-neg-
ative tumors, however, display a somewhat higher expression
of the IgG and STAT1 metagenes.
To verify the actual presence of lymphocytes in those samples
that show a high expression of the respective metagenes we
performed immunohistochemistry using specific antibodies.
CD3 and CD20 were used as markers for T lymphocytes and
B lymphocytes, respectively. Using 10 samples from our own
dataset we observed Spearman rank correlations of 0.79 (P =
0.006) between CD3 and the LCK metagene and of 0.64 (P
= 0.048) between CD20 and the IgG metagene, respectively.
Figure 3a presents a sample with high expression of both the
LCK and IgG metagenes that was characterized by high num-
bers of T cells and B cells in the sample. For an independent
validation of the results we used a dataset from London (Des-
medt and colleagues' dataset GUYU [26]). For 35 samples of
this dataset, pathological information on lymphocytic infiltra-
tion was available. As shown in Figure 3b, a higher expression
of all metagenes was detected in those samples with higher
scoring for lymphocytic infiltration.
Prognostic value of immune-system-related metagenes 
in subgroups of breast cancer patients
There are somewhat differing data in the literature on the fre-
quency of lymphocyte infiltration as indicated by pathological
analysis. While earlier studies reported frequencies of 20% (n
= 382) [45] up to 45% (n = 78) [46], more recent studies
have reported proportions of 16% to 17% (n = 1,919) [8] and
24% (n = 675) [47]. Specific detection of B-lymphocyte infil-
tration has been reported for 20% of invasive breast carcino-
mas [4,48]. Bearing these data in mind we used the upper
quartile (25%) of the samples with highest expression of the
respective metagenes to define a cutoff point for sample strat-
ification. In addition, verification of the robustness by applying
simple median splits of the cohorts led to similar results (data
not shown).
Follow-up information was available for 1,263 out of the 1,781
samples; 929 of these samples were ER-positive and 334
samples were ER-negative. We used multivariate Cox regres-
sion among these 1,263 patients to analyze whether the seven
metagenes provide prognostic information independent from
one another (Additional data file 7). Only for the LCK meta-
gene was a significant result obtained in this analysis (hazards
Table 1
Functional annotation of the immune-system-related metagene clusters
Metagene Incorporated genesa
IgG Most of the genes in this cluster represent genes of immunoglobulins of the immunoglobulin gamma type mainly associated with B 
lymphocytes
HCK This cluster encompasses genes specific for macrophages and cells of the monocyte/myeloid lineage such as hemopoietic cell 
kinase, CD163, Chemokine (C-C motif) receptor 1 (CCR1), complement receptors, and B7-2
MHC-II This cluster contains the HLA-DP, HLA-DQ, HLA-DR genes of the major histocompatability class II complex expressed on the surface 
of professional antigen-presenting cells for their interaction with T cells
LCK Genes in this cluster contain T-cell-specific markers such as CD3, T-cell receptor α, T-cell receptor β, lymphocyte-specific kinase, IL-
7 receptor
MHC-I This cluster contains HLA-A, HLA-B, HLA-C, HLA-F and HLA-G genes of the major histocompatability class I complex common to all 
cell types for the presentation of intracellular antigens
STAT1 The genes in this cluster are associated with interferon signal transduction (like signal transducer and activator of transcription 1 and 
interferon regulatory factor 1 (IRF1)) and are also interferon inducible
Interferon All genes in this cluster represent genes known to be interferon inducible and that are associated with the interferon response of cells
aSee Additional data file 5 for a detailed complete list of all genes.Breast Cancer Research    Vol 11 No 2    Rody et al.
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ratio = 0.6, 95% confidence interval = 0.39 to 0.89; P  =
0.013), while merely a trend was observed for MHC-I (P =
0.11) and STAT1 (P = 0.13) metagenes. To identify those
samples where expression of the LCK metagene has the larg-
est impact on prognosis we performed Kaplan–Meier analyses
of disease-free survival in different tumor subgroups stratified
by ER, HER2, and SCL status. As shown in Figure 4a, the LCK
metagene had the highest prognostic value among the 334
ER-negative samples with a univariate hazard ratio of 1.81
(95% confidence interval = 1.22 to 2.71, P = 0.003). This high
prognostic value was observed in all ER-negative samples
independently of their expression of SCL markers (Figure 4b)
or their HER2 status (Figure 4c). In addition a high prognostic
value of LCK metagene expression was also found among
those 86 ER-positive samples that were also HER2-positive
(ER+/HER2+, P = 0.038) (Figure 4d).
To demonstrate that the LCK metagene was an independent
prognostic factor and not a surrogate marker for other factors,
we performed a multivariate Cox regression analysis including
all clinical variables. These parameters included lymph node
status, age, pathohistological grading, tumor size, HER2 sta-
tus, as well as expression of the LCK metagene. For 124 out
of the 334 ER-negative samples and for 37 out of 86 of the
ER+/HER2+ samples, respectively, all of the parameters were
available. As presented in Tables 2 and 3 regarding the ER-
negative and the ER+/HER2+ samples, respectively, only the
LCK metagene remained a significant factor for disease-free
survival in this analysis, with a hazard ratio of 2.16 (95% con-
fidence interval = 1.15 to 4.03, P = 0.017) and 4.17 (95%
confidence interval = 1.38 to 12.6, P = 0.011).
Discussion
The impact of host factors such as immune cells, stromal envi-
ronment and chemokines on the development and mainte-
nance of breast cancer has frequently been hypothesized, but
still remains a matter of debate (reviewed by Dranoff [49]). In
the present study we identified seven clusters of immune-sys-
tem-related metagenes by large-scale microarray analysis and
showed an association with different immunological cell types.
The redundant information from several highly correlated
ProbeSets allows the construction of robust metagenes that
can be used as surrogate markers for the amount of different
immune cell types in the breast cancer samples. The relation-
ship of these immunological metagenes with other parameters
of the tumors in the combined datasets seems to be complex
since no simple associations were found.
High expression of the LCK metagene predicted for better dis-
ease-free survival among all subgroups of ER-negative tumors
and outperformed all standard parameters in multivariate anal-
ysis. Moreover, a positive prognostic value of LCK metagene
expression was also observed for those ER-positive tumors
with HER2 overexpression. Our results are supported by sev-
eral other recent studies. Ménard and colleagues have shown
Figure 2
Expression of the metagene clusters in immunological cell types Expression of the metagene clusters in immunological cell types. (a) 
The 199 ProbeSets from Figure 1a were used to cluster 44 samples of 
isolated cells and tissues with immune-system-related functions that 
were profiled on Affymetrix U133A arrays by Su and colleagues 
[GEO:GSE1133] [31]. In each case, two samples for the following 
cell/tissue types are presented from left to right: fetal liver (1,2), K-562 
(3,4), whole blood (5,6), CD33 myeloid (7,8), CD14 monocytes (9,10), 
CD34 (11,12), B lymphoblasts (13,14), CD56 natural killer cells 
(15,16), CD4 T cells (17,18), CD8 T cells (19,20), MOLT-4 (21,22), 
Raji (23,24), HL-60 (25,26), Daudi (27,28), CD105 (29,30), CD71 
(31,32), BDCA4 dendritic cells (33,34), CD19 B cells (35,36), thymus 
(37,38), tonsil (39,40), lymph node (41,42), bone marrow (43,44). 
Details about the respective samples are given in Additional data file 
10. HCK, hemopoietic cell kinase; LCK, lymphocyte-specific kinase; 
MHC, major histocompatibility complex; STAT1, signal transducer and 
activator of transcription 1. (b) Representation of the seven metagenes 
that were derived from the 199 ProbeSets as in Figure 1b.Available online http://breast-cancer-research.com/content/11/2/R15
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that lymphocyte infiltration of breast cancer had a strong pos-
itive prognostic value in patients younger than 40 years; how-
ever, no association in patients 40 years or older was shown
[8]. Although the ER status was not analyzed in their study it is
well known that younger age is associated with higher num-
bers of ER-negative tumors. Alexe and colleagues drew a sim-
ilar conclusion analyzing only one dataset (Rotterdam dataset,
n = 286) [9]. They applied a variety of different clustering pro-
cedures to this dataset and proposed to analyze HER2 sam-
ples separately. They identified 651 genes among HER2-
positive samples by principal component analysis that stratify
these samples into two groups. One of the groups was char-
acterized by immune-system-associated genes and improved
survival.
Teschendorff and colleagues used three microarray datasets
from different platforms and applied a recently developed bio-
informatical method to identify subgroups among 186 ER-neg-
ative breast cancers. They identified a cluster of ER-negative
tumors that display higher expression of six immune-system-
related genes and were associated with a better prognosis
[50]. Most recently, Finak and colleagues used laser-captured
microdissection to analyze the stromal compartment of 53
breast tumors [16]. They identified a good-outcome cluster
that was enriched in immune-system-related genes and pre-
dicted improved survival in four datasets from different plat-
forms (n = 1,021 total). This cluster contained 22 different
genes, 16 of which were also present in our complete immune
response cluster. Eight of these 16 genes are included in our
LCKmetagene and two genes in our MHC-I metagene.
Calabrò and colleagues, in a computational screening
approach to dissect the effect of LI on published ER gene sig-
natures, recently showed that LI is associated with longer sur-
vival in ER-negative patients but shorter survival in ER-positive
patients [51]. Moreover, Schmidt and colleagues identified B-
cell and T-cell metagenes (corresponding to the IgG and LCK
metagenes in our study) by hierarchical clustering of 200
untreated breast cancer samples [52]. In contrast to our
results with no prognostic value of the B-cell metagene in
either ER-positive or ER-negative subgroups (Additional data
file 8), these authors identified the B-cell metagene as the
most important prognostic factor outperforming the T-cell
metagene. Several reasons might account for these discrep-
ancies. Schmidt and colleagues used three patient cohorts all
containing only node-negative patients without any adjuvant
Figure 3
Verification of microarray results by histological examination Verification of microarray results by histological examination. (a) Example of the verification of lymphocytic infiltration by immunohistochemistry 
(Frankfurt dataset). Consecutive sections of a tumor sample with high expression of both IgG and lymphocyte-specific kinase (LCK) metagenes 
stained with antibodies against either CD20 or CD3 to detect B lymphocytes and T lymphocytes, respectively. (b) Validation of the correlation of 
immune-system-related metagenes and lymphocytic infiltration in independent data. Expression of different metagenes compared with pathological 
information on lymphocytic infiltration (LI score) from the London dataset (Desmedt and colleagues [26], n = 35). P values determined using the 
Kruskal–Wallis H test. STAT1, signal transducer and activator of transcription 1.Breast Cancer Research    Vol 11 No 2    Rody et al.
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Figure 4
Prognostic value of the lymphocyte-specific kinase metagene in subgroups of breast cancer patients Prognostic value of the lymphocyte-specific kinase metagene in subgroups of breast cancer patients. Samples of the combined dataset were strati-
fied according to the highest quartile of expression of the lymphocyte-specific kinase (LCK) metagene. Kaplan–Meier analyses of disease-free sur-
vival were performed in different tumor subgroups according to estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and 
stem-cell like (SCL) status. (a) The LCK metagene had a highly significant prognostic value among ER-negative samples. This high prognostic value 
was observed in all ER-negative samples independently of (b) their expression of SCL markers or (c) their HER2 status. (d) In addition, a high prog-
nostic value of LCK metagene expression was also found in ER-positive HER2-positive samples.Available online http://breast-cancer-research.com/content/11/2/R15
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therapy. Despite these very homogeneous cohorts, in one of
them the prognostic value of the B-cell metagene was
restricted to the subset of highly proliferating tumors (the dis-
covery cohort Mainz). This specific cohort was characterized
by a lower proportion of ER-negative tumors (22%). The study
of Schmidt and coworkers clearly demonstrate a prognostic
value of lymphocyte metagenes (B-cell and T-cell metagenes).
In contrast to the cohorts in the study by Schmidt and col-
leagues, our sample collective was rather heterogeneous –
containing node-positive samples and many patients treated
with adjuvant therapy (see Additional data file 2). The differ-
ence in our results might therefore be related to different
cohorts and treatments as well as a potential predictive value
of LI for the response to adjuvant therapy. This possibility
could be important since the response rates to neoadjuvant
chemotherapy are generally higher for ER-negative tumors
[53], the very subgroup in which we observed the prognostic
value of the LCK metagene. One hundred and ninety-eight of
the samples from our combined datasets were pretherapeutic
biopsies from patients treated with neoadjuvant chemotherapy
(MDA133 and Frankfurt-2 datasets) [28,29]. In an exploratory
analysis, six out of eight samples (75%) with high expression
of both IgG and LCK metagenes achieved a pathological com-
plete response – in contrast to only 45 out of all 198 samples
(22.7%, P = 0.002; Additional data file 9). The ER status, how-
ever, might have a confounding effect in this analysis since all
six samples were ER-negative. When the samples were further
stratified according to the ER status, only a trend to signifi-
cance (P  = 0.057) was observed in the ER-negative sub-
group. Still, these data suggest that the beneficial effect of the
expression of the LCK metagenes in our analyses might at
least in part be related to a predictive role in chemotherapeutic
treatment.
Despite the observed prognostic and predictive value of LI in
our analyses, the molecular mechanism behind this phenome-
non is not fully clear. Casares and colleagues have reported
that tumor cells dying in response to anthracyclines can
induce an antitumor immune response that depends on cyto-
toxic T cells and dendritic cells [54-56]. These results are in
line with the better response to anthracycline-containing neo-
adjuvant chemotherapy we have observed. While lymphocytes
may secrete cytokines resulting in an antitumor response [57],
however, they might also shift the balance of the cytokine
milieu toward angiogenic factors [58] and inflammatory
cytokines that seem to promote tumor progression [59,60].
Table 2
Multivariate Cox regression of lymphocyte-specific kinase metagene and standard parameters among estrogen receptor-negative 
tumors
Parameter Stratification n1
a n2
a P valueb Hazard ratio 95% confidence interval
Lymphocyte-specific kinase metagene Low vs. high 60 64 0.017 2.16 1.15 to 4.03
Lymph node status LNN vs. N1 89 35 0.059 1.84 0.98 to 3.47
Age >50 years vs. ≤ 50 years 71 53 0.91 0.97 0.53 to 1.78
Pathological grading Poor vs. well/intermediate 83 41 0.97 1.01 0.53 to 1.95
Tumor size >2 cm vs. ≤ 2 cm 76 48 0.078 1.85 0.93 to 3.66
Human epidermal growth factor receptor 2 status Positive vs. negative 45 79 0.78 1.09 0.58 to 2.05
aComplete information on all parameters was available for 124 estrogen receptor-negative samples. bSignificant values presented in bold.
Table 3
Multivariate Cox regression of lymphocyte-specific kinase metagene and standard parameters among estrogen receptor-positive 
HER2-positive tumors
Parameter n1
a n2
a P valueb Hazard ratio 95% confidence interval
Lymphocyte-specific kinase metagene Low vs. high 21 16 0.011 4.17 1.38 to 12.6
Lymph node status LNN vs. N1 24 13 0.438 0.69 0.27 to 1.77
Age >50 years vs. ≤ 50 years 18 19 0.558 1.38 0.47 to 4.09
Pathological grading Poor vs. well/intermediate 19 18 0.097 2.27 0.86 to 5.99
Tumor size >2 cm vs. ≤ 2 cm 15 22 0.405 1.63 0.52 to 5.12
aComplete information on all parameters was available for 37 estrogen receptor-positive human epidermal growth factor receptor 2 (HER2)-
positive samples. bSignificant values presented in bold.Breast Cancer Research    Vol 11 No 2    Rody et al.
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On the one hand, the tumor-associated lymphocytes might be
a marker of an immune response against the tumor. On the
other hand, these lymphocytes could be attracted by the tumor
cells and generate a functional niche by interaction with the
undifferentiated cancer cells. Moreover, whether either modu-
lation of immune response alters the clinical course of breast
cancer patients or whether efficacy of specific anticancer
treatment approaches depends on the existence of defined
tumor host factors and are therefore predictive in some way
should be clarified. As a matter of fact it is clear that immune-
system-related markers are frequently part of many prognostic
and predictive signatures, even though a specific biological
role cannot be assigned to date.
Conclusions
Many prognostic gene signatures has been reported to date
that seem to have high rates of concordance in their outcome
predictions [61]. In a very recent study, however, Wirapati and
coworkers demonstrated that all of these signatures uniformly
identify the same group of low-proliferating ER-positive tumors
as having a good prognosis [62]. In contrast, all ER-negative
tumors are assigned to the poor prognosis group together
with high-proliferating ER-positive tumors by all prognostic
signatures. An important result of the present work is therefore
that the LCK metagene may actually separate the ER-negative
group into those tumors with better or worse prognosis.
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